Clinical Trials Browser

Erlotinib Hydrochloride × Gastrointestinal × Clear all

NCT01660971 2026-03-18

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT00878163 2026-03-17

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT01013649 2026-02-23

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Phase 3 Completed

546 enrolled 29 charts

Gastrointestinal

Pancreatic Intraductal Neoplasms

NCT04449874 2026-02-12

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT04172779 2025-11-20

ECHO-B

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT00885066 2025-09-30

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00954525 2025-05-02

Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00640978 2025-05-01

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Phase 2 Terminated

16 enrolled 4 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT06483555 2025-04-16

PANGEA

Phase 1/2 Recruiting

DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT00739453 2024-11-20

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

Phase 1 Completed

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT02273362 2024-03-26

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

Phase 1/2 Completed

25 enrolled 10 charts

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT01180959 2022-11-07

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Phase 2 Completed

45 enrolled 7 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02961374 2022-07-26

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Phase 2 Completed

46 enrolled 13 charts

Gastrointestinal

Attenuated familial adenomatous polyposis, Adenomatous Polyposis Coli

NCT03086538 2022-06-15

Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms

NCT03110484 2022-06-15

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Phase 2 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT00393068 2022-03-02

Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

Phase 2 Completed

62 enrolled 8 charts

Gastrointestinal

Esophageal Neoplasms

NCT00617708 2022-02-08

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Phase 1/2 Completed

134 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04165031 2021-11-24

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Phase 1/2 Terminated

5 enrolled 9 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT00591123 2021-10-01

Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia

Phase 2 Completed

38 enrolled 14 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasm Metastasis

NCT01210911 2021-04-21

GEM

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT02154737 2021-03-02

Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00376948 2021-03-01

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Completed

20 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00769483 2020-09-03

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

Phase 1/2 Completed

81 enrolled 19 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00313560 2020-06-04

ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

Phase 2 Completed

48 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03403049 2020-04-22

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT00026338 2020-04-02

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

Phase 3 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00539617 2020-03-23

Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery

Phase 2 Terminated

7 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms

NCT02723578 2020-01-13

Pemetrexed and Erlotinib for Metastatic Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT00728000 2019-11-25

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT00733746 2019-10-21

Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Phase 2 Completed

123 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00940316 2019-05-07

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

Phase 2 Completed

28 enrolled 11 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00276744 2018-10-24

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

Phase 2 Terminated

249 enrolled 4 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01782690 2018-07-23

An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

338 enrolled 18 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01561014 2018-07-02

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Phase 1 Completed

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT00832637 2018-06-29

Gem-ox

Phase 2 Terminated

33 enrolled 9 charts

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT00565487 2018-05-21

Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00365144 2018-01-19

Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine

Phase 2 Completed

36 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00033241 2018-01-10

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00040183 2018-01-10

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Phase 3 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT00810719 2018-01-10

Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

Phase 2 Completed

30 enrolled 7 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00881751 2017-09-11

Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

Phase 2 Completed

95 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01693419 2017-08-23

S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT01729481 2017-07-19

ML22774

Phase 2 Unknown

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT00987766 2017-07-02

Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Phase 1 Completed

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Liver Neoplasms, Pancreatic Neoplasms

NCT00841035 2017-05-19

7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients

Phase 2 Terminated

6 enrolled 3 charts

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT00366457 2017-05-15

Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer

Phase 2 Completed

32 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms